H3B 8800

Drug Profile

H3B 8800

Alternative Names: H3B-8800

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator H3 Biomedicine
  • Developer Eisai Inc; H3 Biomedicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia and Chronic myelomonocytic leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 01 Aug 2016 Phase-I clinical trials in Acute myeloid leukaemia in USA (PO) (NCT02841540)
  • 01 Aug 2016 Phase-I clinical trials in Chronic myelomonocytic leukaemia in USA (PO) (NCT02841540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top